Lumosa's LT3001 Receives UK Phase 2 Trial Approval

Obtained trial approvals in 7 European countries

Lumosa to Participate the 2024 BIO International Convention

Center Lab Group Executive Takes Helm as New Lumosa Chairman to Drive Global Licensing of LT3001 Stroke Candidate

Clinical Enrollment on Track, Data Readout Expected by Year-End

Lumosa Partners with Center Lab to Invest in GenEditBio, Targeting Gene Therapy

Lumosa Launching LT3001 Phase 2 Trials in Multiple EU Countries

Lumosa’s Lead Candidate LT3001 for Acute Ischemic Stroke Approaching Key Milestone, Targeting Unblinding in Late 2024